BGLC
BioNexus Gene Lab Corp
Next earnings ≈ Oct 13, 2026 · est. from filing cadence
$2.07
▲ +1.47%$2.07▼ -24.45%
over 1Y
L $1.94EODHDH $11.14
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.5%
1W-14.5%
1M-6.8%
3M-11.9%
YTD-47.5%
1Y-24.5%
Avoid
Conviction
Horizon
Medium (3–12mo)
Conservative balance sheet (liabilities/equity 0.07x); but revenue fell -21.9% YoY.
Revenue (FY2025) $7.42M · FY2025
BioNexus Gene Lab Corp shows $7.42M in FY2025 revenue (-21.9% YoY), a -40.2% net margin, and -34.6% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $13.4M | $10.9M | $9.77M | $9.51M | $7.42M |
| Gross profit | $2.27M | $1.26M | $1.33M | $1.29M | $1.09M |
| Operating income | $1.06M | -$291K | -$2.59M | -$1.57M | -$2.97M |
| Net income | $752K | -$356K | -$2.63M | -$1.60M | -$2.98M |
| Diluted EPS | — | — | -$0.17 | -$0.09 | — |
| Net margin | 5.6% | -3.3% | -26.9% | -16.8% | -40.2% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$2.52M
EV / EBITDA—
EV / Sales0.3
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-59.6%
FCF yield-37.5%
Quality & risk
ROIC (est.)-27.2%
Free cash flow-$1.88M
Total debt—
Net cash$2.49M
Altman Z-Score4.12 safe
Piotroski F-Score4/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-86.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — late filing notice (2026-03-31). Worth a closer look.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-05-292026-06-05open ↗10-QPeriod ending 2026-03-312026-05-15open ↗10-KPeriod ending 2025-12-312026-04-14open ↗NT 10-KPeriod ending 2025-12-312026-03-31open ↗8-KPeriod ending 2026-03-112026-03-17open ↗8-KPeriod ending 2026-02-232026-02-23open ↗8-KPeriod ending 2026-01-282026-02-03open ↗8-KPeriod ending 2025-12-242025-12-30open ↗8-KPeriod ending 2025-12-192025-12-23open ↗DEF 14APeriod ending 2025-12-242025-12-03open ↗8-KPeriod ending 2025-11-282025-12-02open ↗10-QPeriod ending 2025-09-302025-11-14open ↗
Frequently asked
- Is BioNexus Gene Lab Corp (BGLC) a buy?
- BGLC currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.07x); but revenue fell -21.9% YoY.
- What is BioNexus Gene Lab Corp's quality score?
- BGLC scores 47.94117647058823/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001737523, latest 10-Q filed 2026-05-15) · EODHD · as of 6/22/2026, 11:32:39 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.